16. Hidalgo, Maria M., Creusa Hidalgo-Regina, M. Valeria Bahamondes, Ilza Monteiro, Carlos A. Petta, and Luis Bahamondes. “Serum levonorgestrel levels and endometrial thickness during extended use of the levonorgestrel– releasing intrauterine system.” Contraception 80, no. 1 (2009): 84–89; Lakha, F., P.C. Ho, Z.M. Van der Spuy, K. Dada, R. Elton, A.F. Glasier, H.O.D. Critchley, A.R.W. Williams, and D.T. Baird. “A novel estrogen-free oral contraceptive pill for women: multicentre, double-blind, randomized controlled trial of mifepristone and progestogen-only pill (levonorgestrel).” Human Reproduction 22, no. 9 (2007): 2428–2436.
17. Wright, Kristen Page, and Julia V. Johnson. “Evaluation of extended and continuous use oral contraceptives.” Therapeutics and Clinical Risk Management (2008): 906.
18. Там же, 907.
19. “YAZ (Drospirenone/Ethinyl Estradiol) – Official Website.” Accessed March 18, 2017. www.yaz-us.com
20. Helmerhorst, F.M., J.P. Vandenbroucke, C.J.M. Doggen, and F.R. Rosendaal. “The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study.” The BMJ 339 (2009): 1–8.
21. “Thrombosis.” Wikipedia. Accessed August 23, 2017. en.wikipedia.org/wiki/Thrombosis.
22. Hendrickson-Jack, Lisa. “FFP 007 | What the Pill Really Does to Your Hormones | PCOS & Menstrual Irregularities | Dr. Lara Briden.” Fertility Friday Podcast. Podcast Audio, January 30, 2015. fertilityfriday.com/lara
23. Castle, S., and I. Askew. “Contraceptive discontinuation: reasons, challenges, and solutions.” New York: Population Council (2015); 1–33; Berenson, Abbey B., and Constance M. Wiemann. “Contraceptive use among adolescent mothers at 6 months postpartum.” Obstetrics & Gynecology 89, no. 6 (1997): 999–1005; Westhoff, Carolyn L., Stephen Heartwell, Sharon Edwards, Mimi Zieman, Gretchen Stuart, Carrie Cwiak, Anne Davis, Tina Robilotto, Linda Cushman, and Debra Kalmuss. “Oral contraceptive discontinuation: do side effects matter?” American Journal of Obstetrics and Gynecology 196, no. 4 (2007): 412-e1; Peipert, Jeffrey F., Qiuhong Zhao, Jenifer E. Allsworth, Emiko Petrosky, Tessa Madden, David Eisenberg, and Gina Secura. “Continuation and satisfaction of reversible contraception.” Obstetrics and Gynecology 117, no. 5 (2011): 1105.
24. Castle, S., and I. Askew. “Contraceptive discontinuation: reasons, challenges, and solutions.” New York: Population Council (2015); 2–3; Westhoff, Carolyn L., Stephen Heartwell, Sharon Edwards, Mimi Zieman, Gretchen Stuart, Carrie Cwiak, Anne Davis, Tina Robilotto, Linda Cushman, and Debra Kalmuss. “Oral contraceptive discontinuation: do side effects matter?” American Journal of Obstetrics and Gynecology 196, no. 4 (2007): 412e1–412e7.
25. Westfall, John M., Deborah S. Main, and Lynn Barnard. “Continuation rates among injectable contraceptive users.” Family Planning Perspectives (1996): 275–277.
26. Test ID: TTFB Testosterone, Total, Bioavailable, and Free, Serum. TTFB – Clinical: Testosterone, Total, Bioavailable, and Free, Serum. Accessed December 21, 2017. www.mayomedicallaboratories.com/test-catalog/Clinical and Interpretive/83686.
27. Davis, Susan. “Testosterone and sexual desire in women.” Journal of Sex Education and Therapy 25, no. 1 (2000): 25–32.
28. Davis, Susan R., and Jane Tran. “Testosterone influences libido and well being in women.” Trends in Endocrinology & Metabolism 12, no. 1 (2001): 33–37.
29. Zimmerman, Y., M.J.C. Eijkemans, H.J.T. Coelingh Bennink, M.A. Blankenstein, and B.C.J.M. Fauser. “The effect of combined oral contraception on testosterone levels in healthy women: a systematic review and meta-analysis.” Human Reproduction Update 20, no. 1 (2014): 76–105; Crewther, Blair T., Dave Hamilton, Kathleen Casto, Liam P. Kilduff, and Christian J. Cook. “Effects of oral contraceptive use on the salivary testosterone and cortisol responses to training sessions and competitions in elite women athletes.” Physiology & Behavior 147 (2015): 84–90; Greco, Teri, Cynthia A. Graham, John Bancroft, Amanda Tanner, and Helen A. Doll. “The effects of oral contraceptives on androgen levels and their relevance to premenstrual mood and sexual interest: a comparison of two triphasic formulations containing norgestimate and either 35 or 25 μg of ethinyl estradiol.” Contraception 76, no. 1 (2007): 8–17; Biswas, Arijit, Osborne A.C. Viegas, Herjan J.T. Coeling Bennink, Tjeerd Korver, and Shan S. Ratnam. “Effect of Implanon use on selected parameters of thyroid and adrenal function.” Contraception 62, no. 5 (2000): 247–251; Segall-Gutierrez, Penina, Joanna Du, Chunying Niu, Marshall Ge, Ian Tilley, Kelly Mizraji, and Frank Z. Stanczyk. “Effect of subcutaneous depo– medroxyprogesterone acetate (DMPA-SC) on serum androgen markers in normal-weight, obese, and extremely obese women.” Contraception 86, no. 6 (2012): 739–745.
30. Zimmerman, Y., M.J.C. Eijkemans, H.J.T. Coelingh Bennink, M.A. Blankenstein, and B.C.J.M. Fauser. “The effect of combined oral contraception on testosterone levels in healthy women: a systematic review and meta-analysis.” Human Reproduction Update 20, no. 1 (2014): 76–105.
31. Anderson, David C. “Sex-hormone-binding globulin.” Clinical Endocrinology 3, no. 1 (1974): 72.
32. Panzer, Claudia, Sarah Wise, Gemma Fantini, Dongwoo Kang, Ricardo Munarriz, Andre Guay, and Irwin Goldstein. “Impact of oral contraceptives on sex hormone-binding globulin and androgen levels: a retrospective study in women with sexual dysfunction.” The Journal of Sexual Medicine 3, no. 1 (2006): 104–113; Zimmerman, Y., M.J.C. Eijkemans, H.J.T. Coelingh Bennink, M.A. Blankenstein, and B.C.J.M. Fauser. “The effect of combined oral contraception on testosterone levels in healthy women: a systematic review and meta-analysis.” Human Reproduction Update 20, no. 1 (2014): 76–105; Hugon-Rodin, Justine, Martine Alhenc-Gelas, H. Coenraad Hemker, Sylvie Brailly-Tabard, Anne Guiochon-Mantel, Geneviève Plu-Bureau, and Pierre-Yves Scarabin. “Sex hormone-binding globulin and thrombin generation in women using hormonal contraception.” Biomarkers (2016): 1–5; Van Vliet, Huib A.A.M., Marijke Frolich, M. Christella, L.G.D. Thomassen, Carine J.M. Doggen, Frits R. Rosendaal, Jan Rosing, and Frans M. Helmerhorst. “Association between sex hormone-binding globulin levels and activated protein C resistance in explaining the risk of thrombosis in users of oral contraceptives containing different progestogens.” Human Reproduction 20, no. 2 (2005): 563–568.
33. Panzer, Claudia, Sarah Wise, Gemma Fantini, Dongwoo Kang, Ricardo Munarriz, Andre Guay, and Irwin Goldstein. “Impact of oral contraceptives on sex hormone-binding globulin and androgen levels: a retrospective study in women with sexual dysfunction.” The Journal of Sexual Medicine 3, no. 1 (2006): 108.
34. Там же, 110.
35. Там же, 110.
36. Mes-Krowinkel, Miranda G., Yvonne V. Louwers, Annemarie G.M.G.J. Mulders, Frank H. de Jong, Bart C.J.M. Fauser, and Joop S.E. Laven. “Influence of oral contraceptives on anthropomorphometric, endocrine, and metabolic profiles of anovulatory polycystic ovary syndrome patients.” Fertility and Sterility 101, no. 6 (2014): 1757–1765.
37. Bouchard, Céline, Jacques Brisson, Michel Fortier, Carol Morin, and Caty Blanchette. “Use of oral contraceptive pills and vulvar vestibulitis: a case-control study.” American Journal of Epidemiology 156, no. 3 (2002): 254–261; Bohm-Starke, Nina, Ulrika Johannesson, Marita Hilliges, Eva Rylander, and Erik Torebjörk. “Decreased mechanical pain threshold in the vestibular mucosa of women using oral contraceptives: A contributing factor in vulvar vestibulitis?” The Journal of Reproductive Medicine 49, no. 11 (2004): 888–892; Battaglia, Cesare, Elena Morotti, Nicola Persico, Bruno Battaglia, Paolo Busacchi, Paolo Casadio, Roberto Paradisi, and Stefano Venturoli. “Clitoral vascularization and sexual behavior in young patients treated with drospirenone – ethinyl estradiol or contraceptive vaginal ring: a prospective, randomized, pilot study.” The Journal of Sexual Medicine 11, no. 2 (2014): 471–480.
Читать дальше
Конец ознакомительного отрывка
Купить книгу